Rate, Risk Factors, and Outcomes of Invasive Fungal Infections in Patients with Hematologic Malignancies

Background: Invasive fungal infections (IFIs) are a significant cause of mortality and morbidity in patients with hematological malignancies. Given the considerable prevalence and consequences of IFIs, hence revealing the exact cause of fungal infections, their rate, associated risk factors, and complications could contribute to reducing both financial and life costs, choosing targeted antifungal treatment, and avoiding unnecessary toxic treatments in individuals who are not suffering from mycoses.

Materials and Methods: This prospective cross-sectional study was conducted in the first semester of 2019. All patients with hematologic malignancies (HM) admitted to Dr. Shariati Hospital were studied. Only those with probable/proven IFIs defined according to the last update of EORTC/MSG criteria were included in the study. The demographic and clinical data were recorded from the hospital information registration system using a questionnaire. Statistical analysis was performed using SPSS software version 24.

Results: Out of 1109 HM patients hospitalized during the study period, 67 (6.04%) IFIs were diagnosed. Of these, 57 (85.04%) were aspergillosis, 7 (10.4%) were mucormycosis, and 3 patients developed other fungal infections. Males constituted 67.2% of the entire IFI population. The mean±SD age of the samples was 43.16 ± 13.8 years. The most common type of malignancy was AML. Lung imaging showed lesions associated with fungal infections in 52 cases (77.6%), with multiple nodules as the most prevalent pattern being observed in 64.2% of cases. Sinus involvement was evidenced in the PNS CT scan of 46 (68.6%) patients. The attributable mortality rate for IFIs was 62.7%. Both the types of IFI and malignancies had no significant relationship with the outcome of patients. Central venous catheter, mucositis, and antibiotic use were the most frequent risk factors.

Conclusion: IFI represents a frequent complication for HM patients with high mortality. Aspergillus species are the predominant etiology in these settings. Considering our results, in high-risk patients, manifestations of warning signs in the sinus and lungs, which would not be cleared despite receiving antibiotics, should raise the possibility of IFIs.

1. Auberger J, Lass-Flörl C, Ulmer H, et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. International journal of hematology. 2008; 88:508-15.
2. Hagberg KW, Li L, Peng M, et al. Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. J Clin Rheumatol. 2016;22(5):241-7.
3. Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112(11):2493-9.
4. Colombo A, de Almeida Júnior J, Slavin MA, et al. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis. 2017;17(11):e344-e356.
5. Ramos ER, Jiang Y, Hachem R, et al. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. Oncologist. 2011;16(7):1049-60.
6. Nguyen MH, Leather H, Clancy CJ, et al. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant. 2011;17(7):1043-50.
7. Akhrass FA, Debiane L, Abdallah L, et al. Palatal mucormycosis in patients with hematologic malignancy and stem cell transplantation. Med Mycol. 2011;49(4):400-5.
8. Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother. 2011;55(11):5018-21.
9. Herbrecht R, Bories P, Moulin JC, et al. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci. 2012:1272:23-30
10. Mühlemann K, Wenger C, Zenhäusern R, et al. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia. 2005;19(4):545-50.
11. Badiee P, Hadadi P, Zareifar S, et al. Prevalence of fungal infections in children with hematologic disorders and determination of anti-fungal susceptibility in isolated species. J Kerman Univ. Medical Sci. 2015;22(4):410-23.
12. Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2012;96(6):748-57.
13. Sheikhbahaei S, Mohammadi A, Sherkat R, et al. Invasive fungal infection in febrile patients with hematologic malignancies undergoing chemotherapy in Iran. Endocr Metab Immune Disord Drug Targets. 2019;19(3):302-307.
14. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367-1376.
15. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068-75.
16. Lin GL, Chang HH, Lu CY, et al. Clinical characteristics and outcome of invasive fungal infections in pediatric acute myeloid leukemia patients in a medical center in Taiwan. J Microbiol Immunol Infect. 2018;51(2):251-259.
17. de León-Borrás R, DelPilar-Morales E, Rivera-Pérez N, et al. Factors associated to invasive fungal infection in hispanic patients with hematological malignancies. Bol Asoc Med P R. 2017;109(1):43-48.
18. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011:3:175-91.
19. Lewis RE, Albert ND, Liao G, et al. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother. 2010;54(3):1298-304.
20. Kazak E, Aslan E, Akalın H, et al. A mucormycosis case treated with a combination of caspofungin and amphotericin B. J Mycol Med. 2013;23(3):179-84.
21. Muhammed M, Anagnostou T, Desalermos A, et al. Fusarium infection: report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore). 2013;92(6):305-316.
22. Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55(2):532-8.
23. Ha JF, Italiano CM, Heath CH, et al. Candidemia and invasive candidiasis: a review of the literature for the burns surgeon. Burns. 2011;37(2):181-95.
24. Mishra P, Agrawal N, Bhurani D, et al. Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy. Indian J Hematol Blood Transfus. 2020;36(1):64-70.
25. Korula A, Abraham A, Abubacker FN, et al. Invasive fungal infection following chemotherapy for acute myeloid leukaemia—experience from a developing country. Mycoses. 2017;60(10):686-91.
26. Yong MK, Slavin MA, Kontoyiannis DP. Invasive fungal disease and cytomegalovirus infection: is there an association? Curr Opin Infect Dis. 2018;31(6):481-489.
27. Marchesi F, Pimpinelli F, Ensoli F, et al. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. Hematol Oncol. 2018;36(2):381-391.
28. Xuan L, Huang F, Fan Z, et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol. 2012; 2:5:46.

Files	XML PDF (1MB)
Issue	Vol 18, No 1 (2024)
Section	Original Article(s)
DOI	https://doi.org/10.18502/ijhoscr.v18i1.14746
Keywords
Hematologic malignancy; Invasive fungal infection; Aspergillosis; AML; Risk factors

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Afhami S, Adibimehr A, Mousavi SA, Vaezi M, Montazeri M, Salehi M, Meidani M, Saleh M, Ahmadikia K, Roilides E, Maertens J, Alijani N. Rate, Risk Factors, and Outcomes of Invasive Fungal Infections in Patients with Hematologic Malignancies. Int J Hematol Oncol Stem Cell Res. 2024;18(1):75-82.

Vancouver

Download Citation